



PHOTO CREDITS: FIND/ JOHN RAE

Industry partnerships to pioneer new advances in diagnostic testing

DIAGNOSTIC TESTING FOR HEALTHY LIVES

Quality, timely diagnostics are key to achieving health for all. The foundation of treatment and public health decision-making, early diagnosis has been consistently linked to improved health outcomes, as well as providing critical data to inform disease management and surveillance. Despite this fact, diagnostics remain the weakest link in the care cascade. In today's modern world, critical gaps in the development of – and access to – affordable, fit-for-purpose diagnostic tools undermine progress towards universal health coverage and threaten our ability to respond to health emergencies.

1.1 million premature deaths in low- and middle-income countries (LMICs) could be avoided annually by reducing the diagnostic gap for six priority conditions.*1

ABOUT FIND

FIND, seeks to ensure equitable access to reliable diagnosis around the world. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems.

Established in 2003, FIND works with local, regional and global partners to accelerate the development, production and roll-out of fit-for-purpose tests.

CLOSING THE DIAGNOSTIC GAP

With almost 20 years' operational experience, we help innovators pioneer transformative solutions and navigate the complexities of product development, validation, and endorsement. We also work with in-country partners to promote and enable key market access, and build diagnostic capacity in LMICs.

Together, we can inspire innovation and drive new progress in diagnostics to address current global health challenges and strengthen health systems for the future.

1 in 2
people across the world still has **little to no access to diagnostic testing**¹



60%
of WHO "Blueprint" pathogens with the greatest outbreak potential have no diagnostic test²



PROGRAMMES

ANTIMICROBIAL RESISTANCE • FEVER & MALARIA • HEPATITIS
NEGLECTED TROPICAL DISEASES • NON-COMMUNICABLE DISEASES
PANDEMIC THREATS • TUBERCULOSIS • WOMEN'S HEALTH



PROJECTS
 ● R&D
 ● Clinical trials
 ● Access
 ○ Offices

1. Fleming KA *et al. Lancet* 2021 398(10315):1997-2050.
 2. Kelly -Cirino CD *et al. BMJ Glob Health* 2019;4:e001179.

* Diabetes, hypertension, HIV, and tuberculosis in the overall population, and hepatitis B virus infection and syphilis for pregnant women.

PARTNERSHIPS IN ACTION

Partnerships are the backbone of our work. Together, we can accelerate product development, bring much-needed transparency to the diagnostic market, and generate new data to inform decision-making at every level. Working hand in hand with researchers, developers, and manufacturers, we provide a combination of bespoke support and open access resources to drive forward solutions from concept and feasibility to validation, manufacturing, and roll-out.



20 YEARS' OPERATIONAL EXPERIENCE

- Expert guidance and support
- Established partnership networks
- Training and capacity building
- Funding and investment



BESPOKE PARTNER SUPPORT

- Technology assessment
- Development planning
- Clinical evaluations
- Technology transfers
- Roll-out and access



OPEN ACCESS RESOURCES

- Product landscaping
- Market insights
- Biobank services
- Target product profiles
- Online test directories


FIND 2015–2020 STRATEGY IN NUMBERS

15	4	29	19	>9,400	3,500
new diagnostic technologies enabled	multi-disease platforms supported	target product profiles developed	WHO recommendations supported	health workers trained	laboratories and facilities strengthened

SPOTLIGHTS

PIONEERING THE DEVELOPMENT OF TRANSFORMATIVE TECHNOLOGIES

A game changer in the field of hepatitis C virus (HCV), the upcoming [HCV core antigen rapid diagnostic test \(RDT\)](#) is designed to simplify diagnostic algorithms and enable decentralized point-of-care testing.



BRINGING LOCAL INNOVATION TO GLOBAL SCALE

Supported assay development and multi-centre studies to help secure [WHO endorsement of Truenat™](#) – India's first point-of-care molecular tuberculosis test – and bring it to a global market.



EXPANDING LOCAL AND GLOBAL MANUFACTURING CAPACITY

As part of the ACT-Accelerator, FIND supported [capacity building and technology transfers in Asia, South America and Africa](#) to help secure the production and supply of COVID-19 antigen RDTs in LMICs.



PHOTO CREDITS: FIND/BEN PHILLIPS/RYAN RUZZESSEY/GEREMEW

PARTNER WITH US

As we work to close the gap in diagnostic testing, we are looking to expand our partnership network. Opportunities to partner with FIND are advertised through an open, transparent, and objective request for proposals process, tendered through our [organizational website](#).

Help break new ground in diagnostic testing.

For more information, please contact: info@finddx.org

www.finddx.org

